All In Biotech

Drug Trial Radar · NCT06712823

An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia

An Open-label, Long-term Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia (CALM2-CAH)

Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Feb 25, 2025

Primary completion

Jul 2029

Study completion Aug 2029

Sponsor

Lead sponsor
Crinetics Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Dec 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of atumelnant (CRN04894).

Conditions

  • Congenital Adrenal Hyperplasia
  • Classic Congenital Adrenal Hyperplasia

Interventions

  • atumelnant (CRN04894)Drug

    Atumelnant is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) receptor antagonist.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (TEAEs), including treatment-emergent serious adverse events (SAEs), adverse events of special interest (AESI [adrenal insufficiency]) and any adverse events (AEs) leading to discontinuationTime frame: Week 108
  2. Incidence of glucocorticoid (GC) deficiency / adrenal insufficiency and adrenal crisisTime frame: Week 108
  3. Incidence of hospitalizations related to congenital adrenal hyperplasia (CAH)Time frame: Week 108
  4. Change from baseline in morning (before 11:00 AM) serum androstenedione (A4) over timeTime frame: Week 108

Locations

13 sites in 6 countries. Site status is shown where the registry gives one.

  • Crinetics Study Site, Minneapolis, Minnesota 55454

    Minneapolis, Minnesota · Active not recruiting

  • Crinetics Study Site

    Morehead City, North Carolina · Active not recruiting

  • Crinetics Study Site

    Philadelphia, Pennsylvania · Active not recruiting

  • Crinetics Study Site

    Córdoba, Córdoba Province, Argentina · Recruiting

  • Crinetics Study Site

    Rio de Janeiro, Brazil · Recruiting

  • Crinetics Study Site

    São Paulo, Brazil · Recruiting

  • Crinetics Study Site

    Curitiba, Paraná, Brazil · Recruiting

  • Crinetics Study Site

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Crinetics Study Site

    Botucatu, São Paulo, Brazil · Recruiting

  • Crinetics Study Site

    Munich, Bavaria, Germany · Recruiting

  • Crinetics Study Site

    Roma, Italy · Recruiting

  • Crinetics Study Site

    Birmingham, United Kingdom · Recruiting

  • Crinetics Study Site

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.